135 related articles for article (PubMed ID: 12813914)
41. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.
Osorio Y; Ghiasi H
J Virol; 2005 Mar; 79(6):3297-308. PubMed ID: 15731224
[TBL] [Abstract][Full Text] [Related]
42. The Race between Host Antiviral Innate Immunity and the Immune Evasion Strategies of Herpes Simplex Virus 1.
Zhu H; Zheng C
Microbiol Mol Biol Rev; 2020 Nov; 84(4):. PubMed ID: 32998978
[TBL] [Abstract][Full Text] [Related]
43. Human antibodies to herpes simplex virus type 1 glycoprotein C are neutralizing and target the heparan sulfate-binding domain.
Adamiak B; Trybala E; Mardberg K; Johansson M; Liljeqvist JA; Olofsson S; Grabowska A; Bienkowska-Szewczyk K; Szewczyk B; Bergstrom T
Virology; 2010 May; 400(2):197-206. PubMed ID: 20176392
[TBL] [Abstract][Full Text] [Related]
44. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone.
Meseda CA; Elkins KL; Merchlinsky MJ; Weir JP
J Infect Dis; 2002 Oct; 186(8):1065-73. PubMed ID: 12355355
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of apoptotic and anti-apoptotic genes on efficacy of DNA vaccine encoding glycoprotein B of Herpes Simplex Virus type 1.
Parsania M; Bamdad T; Hassan ZM; Kheirandish M; Pouriayevali MH; Sari RD; Jamali A
Immunol Lett; 2010 Feb; 128(2):137-42. PubMed ID: 20026118
[TBL] [Abstract][Full Text] [Related]
46. Herpes simplex virus genes Us3, Us5, and Us12 differentially regulate cytotoxic T lymphocyte-induced cytotoxicity.
Aubert M; Krantz EM; Jerome KR
Viral Immunol; 2006; 19(3):391-408. PubMed ID: 16987059
[TBL] [Abstract][Full Text] [Related]
47. Innate and acquired immunity to herpes simplex virus type 1.
Halford WP; Veress LA; Gebhardt BM; Carr DJ
Virology; 1997 Sep; 236(2):328-37. PubMed ID: 9325240
[TBL] [Abstract][Full Text] [Related]
48. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
[TBL] [Abstract][Full Text] [Related]
49. Immune mechanisms induced by an HSV-1 mutant strain: Discrepancy analysis of the immune system gene profile in comparison with a wild-type strain.
Zhang X; Jiang Q; Xu X; Wang Y; Liu L; Lian Y; Li H; Wang L; Zhang Y; Jiang G; Zeng J; Zhang H; Han JJ; Li Q
Vaccine; 2018 Apr; 36(18):2394-2402. PubMed ID: 29602705
[TBL] [Abstract][Full Text] [Related]
50. Herpes simplex virus type 1 envelope subunit vaccine not only protects against lethal virus challenge, but also may restrict latency and virus reactivation.
Rajcáni J; Sabó A; Mucha V; Kostál M; Compel P
Acta Virol; 1995 Feb; 39(1):37-49. PubMed ID: 7572468
[TBL] [Abstract][Full Text] [Related]
51. Intravascular naked DNA vaccine encoding glycoprotein B induces protective humoral and cellular immunity against herpes simplex virus type 1 infection in mice.
Cui FD; Asada H; Kishida T; Itokawa Y; Nakaya T; Ueda Y; Yamagishi H; Gojo S; Kita M; Imanishi J; Mazda O
Gene Ther; 2003 Dec; 10(25):2059-66. PubMed ID: 14595378
[TBL] [Abstract][Full Text] [Related]
52. An analysis of the in vitro and in vivo phenotypes of mutants of herpes simplex virus type 1 lacking glycoproteins gG, gE, gI or the putative gJ.
Balan P; Davis-Poynter N; Bell S; Atkinson H; Browne H; Minson T
J Gen Virol; 1994 Jun; 75 ( Pt 6)():1245-58. PubMed ID: 8207391
[TBL] [Abstract][Full Text] [Related]
53. Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity.
Brockman MA; Knipe DM
J Virol; 2002 Apr; 76(8):3678-87. PubMed ID: 11907207
[TBL] [Abstract][Full Text] [Related]
54. The herpes virus Fc receptor gE-gI mediates antibody bipolar bridging to clear viral antigens from the cell surface.
Ndjamen B; Farley AH; Lee T; Fraser SE; Bjorkman PJ
PLoS Pathog; 2014 Mar; 10(3):e1003961. PubMed ID: 24604090
[TBL] [Abstract][Full Text] [Related]
55. Herpes Simplex Virus Evasion of Early Host Antiviral Responses.
Tognarelli EI; Palomino TF; Corrales N; Bueno SM; Kalergis AM; González PA
Front Cell Infect Microbiol; 2019; 9():127. PubMed ID: 31114761
[TBL] [Abstract][Full Text] [Related]
56. Innate Immune Mechanisms and Herpes Simplex Virus Infection and Disease.
Kurt-Jones EA; Orzalli MH; Knipe DM
Adv Anat Embryol Cell Biol; 2017; 223():49-75. PubMed ID: 28528439
[TBL] [Abstract][Full Text] [Related]
57. Responses of herpes simplex virus type 1-infected cells to the presence of extracellular antibodies: gE-dependent glycoprotein capping and enhancement in cell-to-cell spread.
Rizvi SM; Raghavan M
J Virol; 2003 Jan; 77(1):701-8. PubMed ID: 12477873
[TBL] [Abstract][Full Text] [Related]
58. Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo.
Lubinski JM; Wang L; Soulika AM; Burger R; Wetsel RA; Colten H; Cohen GH; Eisenberg RJ; Lambris JD; Friedman HM
J Virol; 1998 Oct; 72(10):8257-63. PubMed ID: 9733869
[TBL] [Abstract][Full Text] [Related]
59. Autophagy and viral neurovirulence.
Orvedahl A; Levine B
Cell Microbiol; 2008 Sep; 10(9):1747-56. PubMed ID: 18503639
[TBL] [Abstract][Full Text] [Related]
60. Glycoprotein C of herpes simplex virus type 1 prevents complement-mediated cell lysis and virus neutralization.
Harris SL; Frank I; Yee A; Cohen GH; Eisenberg RJ; Friedman HM
J Infect Dis; 1990 Aug; 162(2):331-7. PubMed ID: 2165106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
